It was found that the patient leaflet regarding recommended dosing was inconsistent with the Summary of Product Characteristics, which could lead to incorrect use of the product and overdose manifested by unintended increased volume of bronchial secretions. Potential effects: overdose, increased bronchial secretion, respiratory complications.
Download the app and stay informed
Get instant notifications about recalled products and protect your family.
Important Information
Patients should use Flegafortan in accordance with the current leaflet and the recommendations of a doctor or pharmacist; in case of any doubts about dosing, they should consult a healthcare professio...
The decision to withdraw batch 0131G of Flegafortan 1.6 mg/ml, syrup from the national market was revoked after the leaflet was updated and correct repackaging in line with Good Manufacturing Practice...
If you feel unwell after consuming this product, contact your doctor or call the poison control center.
FAQ
Related